Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products
Investigative Ophthalmology & Visual Science2007Vol. 48(2), pp. 858–858
Citations Over TimeTop 10% of 2007 papers
Yuichi Kaji, Tomohiko Usui, Susumu Ishida, Kenji Yamashiro, Tara Moore, Jonathan E. Moore, Yasuhiko Yamamoto, Hiroshi Yamamoto, Anthony P. Adamis
Abstract
This study further demonstrates the role of the AGEs and RAGE axis in blood-retinal barrier breakdown and the retinal leukostasis, which are characteristic clinical symptoms of diabetic retinopathy. Furthermore, these data demonstrate that blocking AGE bioactivity may be effective for the treatment of diabetic retinopathy.
Related Papers
- → The Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal-Derived AGEs(2014)182 cited
- → Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk(2014)68 cited
- [AGEs and RAGE - advanced glycation end-products and their receptor in questions and answers].(2014)
- → ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTORS IN CARDIOVASCULAR DISEASES(2019)4 cited
- The pathogenesis of receptor for advanced glycation end products in diabetic chronic complication(1999)